NCT06643754View on ClinicalTrials.gov

A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

December 10, 2024

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Advanced Solid Tumors
Interventions
DRUG

SHR-3276

"Dose Escalation: SHR-3276 will be administered intravenously. 4 dose levels are preset.~Dose Expansion: 2 to 3 dose cohorts will be selected for dose expansion stage.~Indication Expansion: Indications will be selected to evaluate preliminary efficacy."

Trial Locations (1)

400037

RECRUITING

The Second Affiliated Hospital of PLA Army Medical University, Chongqing

All Listed Sponsors
lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY